VEA
ADVM

Virtus ETF Advisers’s Adverum Biotechnologies ADVM Stock Holding History

Virtus ETF Advisers’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,777
Closed -$125K – 377
2021
Q3 		$125K Sell
5,777
-302
-5% -$7.71K 0.06% 368
2021
Q2 		$213K Buy
6,079
+3,935
+184% +$212K 0.09% 297
2021
Q1 		$211K Buy
2,144
+38
+2% +$4.56K 0.09% 318
2020
Q4 		$228K Buy
2,106
+660
+46% +$81.7K 0.09% 331
2020
Q3 		$149K Sell
1,446
-197
-12% -$29.5K 0.08% 314
2020
Q2 		$343K Sell
1,643
-1,768
-52% -$313K 0.16% 271
2020
Q1 		$333K Sell
3,411
-497
-13% -$57.9K 0.14% 215
2019
Q4 		$450K Buy
3,908
+1,573
+67% +$139K 0.07% 219
2019
Q3 		$127K Sell
2,335
-130
-5% -$14.7K 0.03% 280
2019
Q2 		$293K Buy
+2,465
New +$204K 0.06% 225
2018
Q4 		– Sell
-8,300
Closed -$502K – 309
2018
Q3 		$502K Sell
8,300
-6,095
-42% -$342K 0.05% 121
2018
Q2 		$763K Buy
+14,395
New +$866K 0.67% 60

Other funds holding ADVM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Virtus ETF Advisers's ADVM Position: Q4 2021 in Review

Virtus ETF Advisers sold out of Adverum Biotechnologies (ADVM) in Q4 2021, closing a stake of 5,777 shares — an estimated $125K sold.

Virtus ETF Advisers first reported a position in ADVM in Q2 2018 and held it in 12 quarters. The position peaked at $763K in Q2 2018. 98 funds tracked by Wall St. Rank hold ADVM as of Q4 2021.

  • Virtus ETF Advisers reported no remaining Adverum Biotechnologies position as of Q4 2021 after selling out during the quarter.
  • Virtus ETF Advisers sold 5,777 Adverum Biotechnologies shares in Q4 2021, an estimated $125K.
  • Virtus ETF Advisers first reported a position in Adverum Biotechnologies in Q2 2018 and held it in 12 quarters.
  • Virtus ETF Advisers's Adverum Biotechnologies position peaked at $763K in Q2 2018.
  • 98 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2021.

Based on Virtus ETF Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.